Pink SheetEisai plans to launch Leqembi (lecanemab) in Germany and Austria in fiscal year 2025 and will stagger the drug’s launch in other EU countries over the next few years, following the approval of the ear
ScripEisai plans to launch Leqembi (lecanemab) in Germany and Austria in fiscal year 2025 and will stagger the drug’s launch in other EU countries over the next few years, following the approval of the ear
ScripIn the past few months, South Korean bioventures, including ABL Bio , have clinched a series of large-scale global out-licensing deals, dominating the transactions in the country so far this year. So
ScripThe recent American College of Cardiology (ACC) conference should have provided companies with the chance to share positive trial updates and saunter into the next trading week with bolstered stock pr